Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 445877

Next Previous
Drug Profile

SAR 445877

Alternative Names: anti-PD-1/IL-15 bi-functional antibody; anti-PD-1/IL-15 fusion protein; KD-050; mut-1N-IL-15/38B2; SAR-445877; SAR-877

Latest Information Update: 17 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kadmon Corporation
  • Developer Sanofi
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B7-H1 antigen inhibitors; Interleukin 15 replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 06 Jul 2026 Sanofi plans a phase II trial for Gastric cancer (Monotherapy, Combination therapy, Inoperable/Unresectable, Late stage disease, Metastatic disease, Second line therapy or greater) and Oesophageal cancer (Monotherapy, Combination therapy, Inoperable/Unresectable, Late stage disease, Metastatic disease, Second line therapy or greater) in undisclosed location (IV) in July 2026 (NCT07692204)
  • 01 Jul 2026 Phase-II clinical trials in Oesophageal cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT07692204)
  • 01 Jul 2026 Phase-II clinical trials in Gastric cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT07692204)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top